Bio-Rad Laboratories, Inc. (BIO.B) stock analysis

P/E against its history

Not enough price and earnings history to compare.

P/E above the industry

Bio-Rad Laboratories's P/E of 45.1 is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 40.7.

EV/EBITDA above its 5-year median

Bio-Rad Laboratories's EV/EBITDA of 172.1 is above its 5-year median of 28.2.

P/B below the industry

Bio-Rad Laboratories's price-to-book of 1.39 is below the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 3.22.

Trading above fair value

The share price of $372.18 is above our fair value estimate of $239.52.

Margin of safety under 20%

The price is 55.4% above fair value, so there is no margin of safety.

Revenue growing under 10% a year

Revenue grew -2.7% a year over the last three fiscal years, short of the 10% we look for.

EPS growth over 3 years

Needs positive EPS three years ago and today.

Earnings growth not accelerating

Net income grew -30.3% over the last twelve months, against a 5-year average of -27.6% a year.

Growing slower than the industry

Revenue grew 1.4% over the last twelve months; the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median is 7.5%.

Guidance lowered

Bio-Rad Laboratories lowered its full-year 2026 currency-neutral revenue outlook on Apr 30, 2026.

Gross margin slipping

Gross margin was 51.9% over the last twelve months, against 52.8% a year earlier.

Return on equity under 15%

Return on equity was 3.1% over the last twelve months and averaged -3.0% over five years; we look for 15% on both.

Return on capital under 10%

Return on invested capital was 0.5%, below the 10% that usually covers the cost of capital.

Return on equity above the industry

Bio-Rad Laboratories's return on equity of 3.1% is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of -0.5%.

Earnings shrank over 5 years

Net income shrank 27.6% a year on average over the last five fiscal years.

Net margin above its 5-year average

Net margin was 8.6% over the last twelve months, against a 5-year average of -10.0%.

Net margin above the industry

Bio-Rad Laboratories's net margin of 8.6% is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of -0.6%.

Low debt

Debt is 11.2% of shareholders' equity, under the 40% we consider low.

Debt rising against equity

Debt to equity rose from 0.1% five years ago to 11.2%.

Debt covered by cash flow

Operating cash flow over the last twelve months equals 61.3% of total debt.

Interest not well covered

Operating income covers interest expense 1.1 times; we look for at least 5.

Short-term assets cover short-term debts

Current assets are 3.14 times current liabilities.

Low bankruptcy risk

The Altman Z-score is 3.55; above 3 is the safe zone and below 1.8 the distress zone.

No dividend

Bio-Rad Laboratories has not paid a dividend in the last twelve months.

Yield against Treasuries

No dividend.

Yield against the market

No dividend.

Dividend stability

No dividend.

Earnings cover

No dividend.

Cash-flow cover

No dividend.